ICOS competitor........
Bayer Corporation Investigates Therapy's Effect on Erectile Function
WEST HAVEN, Conn., Nov. 28 /PRNewswire/ -- Phase II clinical trial results
on a phosphodiesterase V (PDE-V) inhibitor under investigation by Bayer
Corporation for its effect on erectile function will be presented at the
International Society for the Study of Impotence Research (ISIR) meeting on
November 28 in Perth, Australia.
Pre-clinical test results have shown the compound to be potent and highly
selective for the PDE-V enzyme. Development of this compound has progressed
to Phase III clinical trials, which are now underway to determine the
compound's efficacy and safety profile.
"Difficulties with erectile function can impact both health and daily
life. Men need more options for treatment, and we hope to be able to meet
that need," said Wolfgang Plischke, Ph.D., Executive Vice President, Bayer
Corporation, and President, Pharmaceutical Division, North America. "Our
research and development in the field of erectile function enhances our
long-term focus on and commitment to the urology specialty. Bayer is
committed to developing innovative therapies to improve men's health and
quality of life as part of our growing Men's Health Franchise."
Problems with erectile function affect more than 30 million men in the
U.S. Natural erectile function can be lessened due to physical conditions,
such as diabetes or prostate surgery, aging, or psychological conditions.
Currently, there is only one oral FDA-approved therapy option available for
the improvement of erectile function.
Bayer Corporation has demonstrated its commitment to helping men manage
their health through a range of therapies. These products include Cipro(R)
(ciprofloxacin HCl), One-A-Day(R) Men's High Potency Multivitamin/Multimineral
Supplement, and One-A-Day(R) Prostate Health. In addition, a recently
approved once-yearly implant for the palliative treatment of advanced prostate
cancer will be marketed by Bayer Corporation in the first quarter of 2001.
Bayer Corporation is a research-based company with major businesses in
health care, life sciences, and chemicals. The company had 1999 sales of
$8.9 billion and employs approximately 22,200 people. 2000 capital investment
and research and development (R&D) expenditures are projected to total
$1.6 billion. Bayer Corporation is investing $9 billion in capital
expenditures and R&D from 2000 through the year 2004. Bayer Corporation, with
headquarters in Pittsburgh, is a member of the worldwide Bayer Group, a
$29 billion international life sciences, polymers, and specialty chemicals
group based in Leverkusen, Germany.
For more information, contact: Robert Kloppenburg of Bayer Corporation,
203-812-6545; or Wendy Blackburn of Fleishman-Hillard, 816-512-2295.
SOURCE Bayer Corporation |
